Prothymosin α variants isolated from CD8+ T cells and cervicovaginal fluid suppress HIV-1 replication through type i interferon induction

Journal of Infectious Diseases

Volumn 211, Issue 9, 2015, Pages 1467-1475

  Teixeira, Avelino ^a   Yen, Benjamin ^a   Gusella, Gabriele Luca ^a   Thomas, Albert G ^a   Mullen, Michael P ^a   Aberg, Judith ^a   Chen, Xintong ^a   Hoshida, Yujin ^a   Van Bakel, Harm ^a   Schadt, Eric ^a   Basler, Christopher F ^a   García Sastre, Adolfo ^a   Mosoian, Arevik ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

CD8+ T cells; Cervicovaginal lavage; HIV 1; Macrophages; Prothymosin alpha

Indexed keywords

CD8 ANTIGEN; CYTOKINE; INTERFERON; ISOPROTEIN; PROTEIN VARIANT; PROTHYMOSIN ALPHA; SMALL INTERFERING RNA; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; BETA INTERFERON; IL29 PROTEIN, HUMAN; INTERLEUKIN DERIVATIVE; PROTEIN PRECURSOR; THYMOSIN;

ARTICLE; CD8+ T LYMPHOCYTE; DOWN REGULATION; GENE EXPRESSION; GENE TARGETING; GENETIC VARIABILITY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN TISSUE; IMMUNOSURVEILLANCE; INNATE IMMUNITY; MACROPHAGE; NONHUMAN; PRIORITY JOURNAL; PROTALPHA GENE; PROTEIN INDUCTION; PROTEIN ISOLATION; PSEUDOGENE; UTERINE CERVIX MUCUS; VIRUS REPLICATION; AMINO ACID SEQUENCE; ANALOGS AND DERIVATIVES; BODY FLUID; CELL CULTURE; CHEMISTRY; DRUG EFFECTS; FEMALE; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MOLECULAR GENETICS; PHYSIOLOGY;

AMINO ACID SEQUENCE; ANTI-HIV AGENTS; BODY FLUIDS; CD8-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; FEMALE; GENE EXPRESSION REGULATION; HIV-1; HUMANS; INTERFERON TYPE I; INTERFERON-BETA; INTERLEUKINS; MACROPHAGES; MOLECULAR SEQUENCE DATA; PROTEIN PRECURSORS; THYMOSIN; VIRUS REPLICATION;

EID: 84928905808     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiu643     Document Type: Article

References (45)

1. Walker CM, Moody DJ, Stites DP, Levy JA. CD8+ T lymphocyte control of HIV replication in cultured CD4+ cells varies among infected individuals. Cell Immunol 1989; 119:470-5.
2. Cocchi F, DeVico AL, Lu W, et al. Soluble factors from T cells inhibiting X4 strains of HIV are a mixture of beta chemokines and RNases. Proc Natl Acad Sci USA 2012; 109:5411-6.
3. Iqbal SM, Ball TB, Kimani J, et al. Elevated T cell counts and RANTES expression in the genital mucosa of HIV-1-resistant Kenyan commercial sex workers. J Infect Dis 2005; 192:728-38.
4. Mosoian A, Teixeira A, Burns CS, et al. Prothymosin-alpha inhibits HIV-1 via Toll-like receptor 4-mediated type I interferon induction. Proc Natl Acad Sci USA 2010; 107:10178-83.
5. Mosoian A. Intracellular and extracellular cytokine-like functions of prothymosin alpha: implications for the development of immunotherapies. Future Med Chem 2011; 3:1199-208.
6. Uversky VN, Gillespie JR, Millett IS, et al. Natively unfolded human prothymosin alpha adopts partially folded collapsed conformation at acidic pH. Biochemistry 1999; 38:15009-16.
7. Manrow RE, Leone A, Krug MS, Eschenfeldt WH, Berger SL. The human prothymosin alpha gene family contains several processed pseu-dogenes lacking deleterious lesions. Genomics 1992; 13:319-31.
8. Eschenfeldt WH, Berger SL. The human prothymosin alpha gene is polymorphic and induced upon growth stimulation: evidence using a cloned cDNA. Proc Natl Acad Sci USA 1986; 83:9403-7.
9. Manrow RE, Berger SL. GAG triplets as splice acceptors of last resort. An unusual form of alternative splicing in prothymosin alpha pre-mRNA. J Mol Biol 1993; 234:281-8.
10. Goodall GJ, Dominguez F, Horecker BL. Molecular cloning of cDNA for human prothymosin alpha. Proc Natl Acad Sci USA 1986; 83:8926-8.
11. Emmanouilidou A, Karetsou Z, Tzima E, Kobayashi T, Papamarcaki T Knockdown of prothymosin alpha leads to apoptosis and developmental defects in zebrafish embryos. Biochem Cell Biol 2013; 91:325-32.
12. Pineiro A, Cordero OJ, Nogueira M. Fifteen years of prothymosin alpha: contradictory past and new horizons. Peptides 2000; 21:1433-46.
13. Bowick GC, Soman KV, Wang H, et al. Proteomic analysis of Pichinde virus infection identifies differential expression of prothymosin-alpha. J Biomed Biotechnol 2010; doi: 10.1155/2010/956823.
14. Mosoian A, Teixeira A, High AA, et al. Novel function of prothymosin alpha as a potent inhibitor of human immunodeficiency virus type 1 gene expression in primary macrophages. J Virol 2006; 80:9200-6.
15. Skopeliti M, Kratzer U, Altenberend F, et al. Proteomic exploitation on prothymosin alpha-induced mononuclear cell activation. Proteomics 2007; 7:1814-24.
16. Romani L, Bistoni F, Gaziano R, et al. Thymosin alpha 1 activates dendritic cells for antifungal Th1 resistance through toll-like receptor signaling. Blood 2004; 103:4232-9.
17. Halder SK, Matsunaga H, Yamaguchi H, Ueda H. Novel neuroprotective action of prothymosin alpha-derived peptide against retinal and brain ischemic damages. J Neurochem 2013; 125:713-23.
18. Ueda H. Prothymosin alpha and cell death mode switch, a novel target for the prevention of cerebral ischemia-induced damage. Pharmacol Ther 2009; 123:323-33.
19. Ioannou K, Samara P, Livaniou E, Derhovanessian E, Tsitsilonis OE. Prothymosin alpha: a ubiquitous polypeptide with potential use in cancer diagnosis and therapy. Cancer Immunol Immunother 2012; 61:599-614.
20. Shacklett BL. Immune responses to HIV and SIV in mucosal tissues: 'location, location, location'. Curr Opin HIVAIDS 2010; 5:128-34.
21. Ferre AL, Hunt PW, Critchfield JW, et al. Mucosal immune responses to HIV-1 in elite controllers: a potential correlate of immune control. Blood 2009; 113:3978-89.
22. Wira CR, Fahey JV. The innate immune system: gatekeeper to the female reproductive tract. Immunology 2004; 111:13-5.
23. Carias AM, McCoombe S, McRaven M, et al. Defining the interaction of HIV-1 with the mucosal barriers of the female reproductive tract. J Virol 2013; 87:11388-400.
24. Hirbod T, Nilsson J, Andersson S, et al. Upregulation of interferon-alpha and RANTES in the cervix of HIV-1-seronegative women with high-risk behavior. J Acquir Immune Defic Syndr 2006; 43:137-43.
25. Rubtsov Iu P, Vartapetian AB. New intronless members of human pro-thymosin alpha genes. Mol Biol (Mosk) 1995; 29:1320-5.
26. Liu S, Tobias R, McClure S, Styba G, Shi Q, Jackowski G. Removal of endotoxin from recombinant protein preparations. Clin Biochem 1997; 30:455-63.
27. DeVico AL, Gallo RC. Control of HIV-1 infection by soluble factors of the immune response. Nat Rev Microbiol 2004; 2:401-13.
28. Ueda H, Matsunaga H, Halder SK. Prothymosin alpha plays multifunctional cell robustness roles in genomic, epigenetic, and nongenomic mechanisms. Ann N Y Acad Sci 2012; 1269:34-43.
29. Alvarez-Fernandez L, Gomez-Marquez J. Preliminary methylation analysis of prothymosin alpha genomic sequences. Biochem Cell Biol 2012; 90:596-601.
30. Kobayashi D, Kumagai J, Morikawa T, et al. An integrated approach of differential mass spectrometry and gene ontology analysis identified novel proteins regulating neuronal differentiation and survival. Mol Cell Proteomics 2009; 8:2350-67.
31. Wang KC, Cheng AL, Chuang SE, Hsu HC, Su IJ. Retinoic acid-induced apoptotic pathway in T-cell lymphoma: Identification of four groups of genes with differential biological functions. Exp Hematol 2000; 28:1441-50.
32. Smith MR, al-Katib A, Mohammad R, et al. Prothymosin alpha gene expression correlates with proliferation, not differentiation, of HL-60 cells. Blood 1993; 82:1127-32.
33. Conteas CN, Mutchnick MG, Palmer KC, et al. Cellular levels of thymosin immunoreactive peptides are linked to proliferative events: evidence for a nuclear site of action. Proc Natl Acad Sci USA 1990; 87:3269-73.
34. Evstafieva AG, Belov GA, Rubtsov YP, et al. Apoptosis-related fragmentation, translocation, and properties of human prothymosin alpha. Exp Cell Res 2003; 284:211-23.
35. Matsunaga H, Ueda H. Stress-induced non-vesicular release of prothy-mosin-alpha initiated by an interaction with S100A13, and its blockade by caspase-3 cleavage. Cell Death Differ 2010; 17:1760-72.
36. Mosoian A, Teixeira A, Burns CS, et al. Influence of prothymosin-alpha on HIV-1 target cells. Ann N Y Acad Sci 2007; 1112:269-85.
37. Ryo A, Suzuki Y, Arai M, et al. Identification and characterization of differentially expressed mRNAs in HIV type 1-infected human T cells. AIDS Res Hum Retroviruses 2000; 16:995-1005.
38. Corbeil J, Sheeter D, Genini D, et al. Temporal gene regulation during HIV-1 infection of human CD4+ T cells. Genome Res 2001; 11: 1198-204.
39. Geiss GK, Bumgarner RE, An MC, et al. Large-scale monitoring of host cell gene expression during HIV-1 infection using cDNA microarrays. Virology 2000; 266:8-16.
40. Bartee E, McFadden G. Cytokine synergy: an underappreciated contributor to innate anti-viral immunity. Cytokine 2013; 63:237-40.
41. Munoz-Fontela C, Macip S, Martinez-Sobrido L, et al. Transcriptional role of p53 in interferon-mediated antiviral immunity. J Exp Med 2008; 205:1929-38.
42. Munoz-Fontela C, Gonzalez D, Marcos-Villar L, et al. Acetylation is indispensable for p53 antiviral activity. Cell Cycle 2011; 10:3701-5.
43. Kobayashi T, Wang T, Maezawa M, et al. Overexpression of the onco-protein prothymosin alpha triggers a p53 response that involves p53 acetylation. Cancer Res 2006; 66:3137-44.
44. Ellegard R, Shankar EM, Larsson M. Targeting HIV-1 innate immune responses therapeutically. Curr Opin HIV AIDS 2011; 6:435-43.
45. Harris RS, Hultquist JF, Evans DT. The restriction factors of human immunodeficiency virus. J Biol Chem 2012; 287:40875-83.